Eli Lilly and Company logo

Eli Lilly and Company (LLYC)

Market Open
5 Dec, 09:01
XWBO XWBO
871. 10
+3.4
+0.39%
- Market Cap
104.2 P/E Ratio
5.2% Div Yield
0 Volume
6.64 Eps
867.7
Previous Close
Day Range
871.1 871.1
Year Range
539.1 965
Want to track LLYC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 62 days

Summary

LLYC trading today higher at €871.1, an increase of 0.39% from yesterday's close, completing a monthly increase of 16.32% or €122.2. Over the past 12 months, LLYC stock gained 16.41%.
LLYC pays dividends to its shareholders, with the most recent payment made on Sep 10, 2025. The next announced payment will be in In 5 days on Dec 10, 2025 for a total of €1.5.
The last earnings report, released on Oct 30, 2025, exceeded the consensus estimates by 0.65%. On average, the company has fell short of earnings expectations by -3.68%, based on the last three reports. The next scheduled earnings report is due on Feb 05, 2026.
Eli Lilly and Company has completed 4 stock splits, with the recent split occurring on Oct 16, 1997.
The company's stock is traded on 16 different exchanges and in various currencies, with the primary listing on NYSE (USD).

LLYC Chart

Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seekingalpha | 2 days ago
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website

LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website

Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.

Zacks | 2 days ago
Eli Lilly cuts price of Zepbound in heightened weight-loss drug competition

Eli Lilly cuts price of Zepbound in heightened weight-loss drug competition

Eli Lilly and Co (NYSE:LLY) said on Monday it is lowering the cash prices of its weight-loss drug Zepbound, marking the latest move in a growing price battle with rival Novo Nordisk. The US pharmaceutical giant said single-dose vials of Zepbound will now be available on its direct-to-consumer platform, LillyDirect, at reduced prices.

Proactiveinvestors | 3 days ago

Eli Lilly and Company (LLYC) FAQ

What is the stock price today?

The current price is €871.10.

On which exchange is it traded?

Eli Lilly and Company is listed on NYSE.

What is its stock symbol?

The ticker symbol is LLYC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 5.2%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 7.5.

When is the next earnings date?

The next earnings report will release on Feb 05, 2026.

Has Eli Lilly and Company ever had a stock split?

Eli Lilly and Company had 4 splits and the recent split was on Oct 16, 1997.

Eli Lilly and Company Profile

- Industry
- Sector
David A. Ricks CEO
XWBO Exchange
US5324571083 ISIN
US Country
47,000 Employees
14 Nov 2025 Last Dividend
16 Oct 1997 Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000